Table 5. Hypothetical patient profiles with varying age, donor type, and disease severity.

Data	Patient 1	Patient 2	Patient 3
Patient data
Age at transplant (year)	6	6	16
Age group (year)	≤10	≤10	11-17
Sex	Male	Male	Male
KPS or Lanskya score	<90	<90	<90
HCTb-Comorbidity index (in range)	0-2	0-2	0-2
Recipient CMVc serostatus	Negative	Negative	Negative
Transplant data
Donor	HLAd identical sibling	HLA mismatch relative	HLA identical sibling
Graft type	Bone marrow	Bone marrow	Bone marrow
Donor-recipient HLA matching	8/8	7/8	8/8
Conditioning intensity	Myeloablative	Nonmyeloablative	Myeloablative
Conditioning regimen	Flu/Bue	TBI/Cy/Flu/TTf	Flu/Bu
Serotherapy	ATGg	ATG	ATG
GVHDh prophylaxis	CNI+MTXi	Post-Cy+Siro± MMFj	CNI+MTX
SCDk data
Number of ACSl syndromes within 2 year pre-HCT	0	0	2
Require exchange transfusion	No	No	No
VOCm requiring hospitalization within 2 year pre-HCT	No	No	Yes
Frequency of hospitalizations for VOC	<3 per year	<3 per year	<3 per year

^aKPS: Karnofsky performance status.

^bHCT: hematopoietic cell transplantation.

^cCMV: cytomegalovirus.

^dHLA: human leukocyte antigen.

^eFlu/Bu: fludarabine + busulfan.

^fTBI/Cy/Flu/TT: total body irradiation + cyclophosphamide + fludarabine + thiotepa.

^gATG: anti-thymocyte globulin.

^hGVHD: graft-versus-host disease.

ⁱCNI+MTX: calcineurin inhibitor + methotrexate.

^jPost-Cy+Siro± MMF: post-transplant cyclophosphamide + sirolimus + mycophenolate mofetil.

^kSCD: sickle cell disease.

^lACS: acute chest syndrome.

^mVOC: vaso-occlusive crisis.